Aclarion, Inc., a healthcare technology company focused on innovative pain diagnostics, has completed a registered direct offering of common stock, raising approximately $4.7 million to support its strategic growth initiatives. The company will sell 506,803 shares at $9.25 per share, with the transaction expected to close on January 31, 2025.
The capital raise represents a significant milestone for Aclarion, providing crucial funding to advance its Nociscan platform, a groundbreaking software-as-a-service (SaaS) solution designed to help physicians identify the source of chronic low back pain. By leveraging magnetic resonance spectroscopy (MRS), proprietary signal processing techniques, and augmented intelligence algorithms, Nociscan offers a noninvasive method for distinguishing between painful and nonpainful spinal discs.
The proceeds from this offering will be strategically allocated across multiple critical areas, including market development, clinical evidence generation, product development and quality improvement, and general corporate support. This funding demonstrates Aclarion's commitment to enhancing its technological capabilities and expanding its presence in the healthcare technology sector.
Dawson James Securities, Inc. is serving as the sole placement agent for the offering, which is being conducted under a previously filed shelf registration statement declared effective by the Securities and Exchange Commission. The transaction underscores investor confidence in Aclarion's innovative approach to addressing chronic pain diagnostics.
The company's Nociscan platform represents a potential paradigm shift in low back pain assessment. By providing physicians with detailed insights into disc-related pain through advanced biomarker analysis, the technology could significantly improve treatment strategies and patient outcomes. This offering provides Aclarion with the financial resources necessary to continue refining and expanding its technological solutions.
Investors and healthcare professionals are closely watching Aclarion's progress, as the company continues to develop technologies that could transform pain management and diagnostic methodologies. The successful stock offering positions Aclarion to accelerate its research, development, and market penetration efforts in the coming year.
